Royalty Report: Drugs, ribonucleic acid, Drug Discovery – Collection: 294284

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 8

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8

Primary Industries

  • Drugs
  • ribonucleic acid
  • Drug Discovery
  • Cancer
  • nucleic acid

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 294284

License Grant
For the Option the German Licensor grants the right to request from Licensor for each of the  Licensee targets an option on a non-exclusive and worldwide licence for Licensor IP with the right to sub-license at terms consistent with this Agreement to evaluate, develop and commercialise therapeutic atuRNAis inhibiting the specific Licensee Target agreed upon, the QBI Option.

For the License, upon exercise of each specific option the German Licensor shall grant a non-exclusive license under German IP in accordance with the terms and conditions specified.  Licensor agrees to grant a non-exclusive and worldwide license with the right to sub-license at terms and conditions consistent with this Agreement under the Licensor IP and the know-how relating to the atuRNAi(s) to research, develop, have developed, manufacture, have manufactured, market and sell Licensee Products.

License Property
Licensor IP means the Licensor patents and patent applications as of the date of this Agreement.

atuRNAi(s) shall mean the siRNAs developed by or for Licensor and supplied to Licensee under this Agreement as potential inhibitors of certain molecular drug targets for therapeutic intervention.

Licensee IP means the present and future Patent Rights and Know-How owned by Licensee and directed to the [polypeptides, to nucleic acids encoding the polypeptides, antibodies to the polypeptides, antisense and siRNAJ to the Licensee Target genes and methods of treatment of diseases using these, including but not limited to rights to patents and patent applications.

Licensee Products means Products and Drug Products for the treatment of human diseases covered by Licensee IP.

The property includes Patent application EP 04010700.05 describing the use of lipids in formulations to deliver oligonucleotides into cells and tissues and all equivalent and derived applications including EP 02017601.2], and, PCT application number WO 2004/015107 and all equivalent/derived applications including US Provisional Application 60/402,541, the Licensors core technology patent application.

Field of Use
The field of use is for the treatment of human diseases covered by Licensees IP.  The Licensees primary focus has been for the treatment of diseases associated with oxidative stress and ischemic injury.

Oxidative stress is an imbalance between free radicals and antioxidants in your body. Free radicals are oxygen-containing molecules with an uneven number of electrons. The uneven number allows them to easily react with other molecules.

Ischemic injury is caused by diminished or absent blood flow. The main mechanism of injury in ischemia is hypoxia (as described above).

IPSCIO Record ID: 204368

License Grant
Licensor grants to the Licensee an exclusive world-wide license under the Patent Rights in order to develop, make, have made, use and sell Licensed Products, with the right to sub-license.
License Property
The Invention shall mean the substituted porphyrin compounds and methods of their use,  invented in part, a result of research covered under the First Agreement and designated as Licensor Technology ID No. 2000-15.
Field of Use
The present invention relates to methods of protecting against the deleterious effects of oxidants, particularly, superoxide radicals, hydrogen peroxide and peroxynitrite, and to methods of preventing and treating diseases and disorders that involve or result from oxidant stress.

Oxidative stress is an imbalance between free radicals and antioxidants in your body. Free radicals are oxygen-containing molecules with an uneven number of electrons. The uneven number allows them to easily react with other molecules.

IPSCIO Record ID: 294285

License Grant
For the Exclusive Licenses, Licensor grants an exclusive license including the right to sublicense, under the Licensor Patent Rights and Licensor Technology to develop, make, have made, use, sell, offer for sale and import Biomolecules and Licensed Products in the Territory.

For the Non-Exclusive Research Licenses, Licensor grants a non-exclusive, irrevocable, perpetual license in the Territory, to use solely for research done by Licensee or its Affiliates or by Third Party contractors for Licensee or its Affiliates the Licensor Technology, excluding any Licensor Technology that is now or hereafter during the Term covered by claims in issued patents or published patent applications disclosed to Licensee during the Term.

License Property
Licensor owns or controls certain patents, patent applications, technology,know-how and scientific and technical information relating to Biomolecules and Licensed Products.

Applicable Biomolecule means a Biomolecule as to which Licensor at any time during the Term commenced IND-enabling toxicity studies or clinical trials.

Product means any product, including any pharmaceutical product or diagnostic product, which contains any Biomolecule, either alone or in combination with any other active pharmaceutical ingredient, in all formulations and strengths for all uses.

Combination Product means any pharmaceutical product containing a Biomolecule and one or more other active phannaceutical ingredients.

Field of Use
License relates to Licensor’s human gene RTP-801 and to molecules that modify its expression or function under a new agreement between the two companies. RTP-801 is involved in the development of pathologic blood vessels that accelerate the progression of age-related macular degeneration (AMD).   Based on preclinical models, it is believed that AMD can be treated by blocking the expression of the RTP-801 gene through RNA interference or RNAi.

Licensee has extensive experience and expertise in the development and commercialization of pharmaceutical products.  Licensor is a clinical-stage pharmaceutical company engaged in discovering and developing novel RNAi interference or RNAi-based therapeutics.

IPSCIO Record ID: 294289

License Grant
Licensor grants a non-exclusive right and license under the Licensor Patent Rights-CRT, subject to and under the terms and conditions of the CRT Agreement, for the sole and exclusive purposes of Researching, Developing, having Developed, using, keeping, making, having made, importing, having imported, selling, having sold, Commercializing, and otherwise disposing or offering to dispose of Licensed Products for the Target in the Field in the Territory.
License Property
CRT means Cancer Research Technology Limited licensed patents.

The patent is RNAi uses in mammalian cells.

Licensees target is p53, or Tumor protein p53 (Li-Fraumeni syndrome).

Field of Use
Field means the use of therapeutic RNAi Products against the Target for the treatment of hypoxic injury in humans, including but not limited to renal failure.

Hypoxic injury implies damage to cells resulting only from decreased oxygen tension. This is a relatively unusual pattern of injury in its pure form. Hypoxia can result from decreased atmospheric oxygen concentration, abnormal lung function, and decreased oxygen-carrying capacity in the blood (e.g., severe anemia).

IPSCIO Record ID: 294648

License Grant
For the Development and Commercialization License, the Licensor of the United States and Isreal  grants to the German Licensee an exclusive, world-wide license with the right to sublicense, under the Licensor Existing IP and the Joint Program IP, to develop, manufacture and/or have manufactured and commercialize import, market, sell and otherwise commercialize Licensor Products.

For the Research License, Licensor grants a non-exclusive, world-wide license, without the right to sublicense, under the Licensor Existing IP and the Joint Program IP, to perform the Joint Research Program and the Joint Development Program.

License Property
Licensor Existing IP means the present and future Patent Rights and Know-How owned by Licensor and directed to the 801 polypeptide, to nucleic acid encoding the 801 polypeptide, antibody to the 801 polypeptide, antisense and siRNA to 801 gene and methods of treatment of diseases using these,including but not limited to rights to patents and patent applications.

Licensor Products means Products and Drug Products for the treatment of human diseases other than cancer.

Field of Use
The field of use is for the treatment of human diseases other than cancer.

IPSCIO Record ID: 279354

License Grant
Licensor grants to Irish Licensee an exclusive license under the Licensor Patents to make (subject to Licensor’s manufacturing rights set forth below), use, sell, and offer for sale in any country of the world Licensed Products in the Field. Neither Licensee nor Licensor will have the right to develop or commercialize Licensed Products outside the Field without prior written consent of the other Party.

Licensor grants to Licensee (a) an exclusive license to use in any country of the world any method or composition claimed by the Licensor Patents, and (b) a non-exclusive license to use in any country of the world any Licensor Know-How, to research in the Field Lead Compounds, Development Compounds, Backup Compounds, and Licensed Products.

License Property
Licensed Product means a Development Compound for which the Parties obtain the approval from any Regulatory Authority to sell for use by the general public in the Field.

Licensor Patents means a) the patents and applications listed; b) any application that claims priority to the foregoing patents and applications; and c) any patent that issues from any of the applications described in clauses a) and b) above.
US Patent #6,506,559 – Genetic inhibition by double-stranded RNA
US Patent #6,117,657 – Non-nucleotide containing enzymatic nucleic aci
US Patent #6,586,238 – Enzymatic nucleic acids containing 5-and or 3-cap structures

Lead Compound is a Lead selected by JSC for evaluation in the Field.

Development Compound means a Pre-Development Compound that the JSC has designated for clinical development.

Compound means a composition comprising one or more siNAs as active ingredients, known as of the Effective Date or discovered pursuant to this Agreement subsequent to that date, against the Licensee Named Targets in the Field.

Backup Compound means a Lead Compound that the JSC has selected as a backup candidate for clinical development.

JSC means the Joint Steering Committee.

Field of Use
Field means conditions and diseases affecting the eve and treatments for such conditions and diseases. Such conditions and diseases include, for example, diabetic retinopathy and ocular adenoviral infection, but this does not mean that the Field encompasses the treatment outside the eye of diabetes or adenoviral infection, respectively.

Licensee is to develop Sirna-027, a RNAi-based therapeutic currently in Phase 1 for age-related macular degeneration (AMD), and to discover and develop other RNAi-based therapeutics against select gene targets in ophthalmic diseases.

IPSCIO Record ID: 344587

License Grant
Licensor grants to the Canadian Licensee an exclusive, worldwide license under the Licensor Product-Specific Technology Patents and the Joint Patents to any Product-Specific Technology and under the Licensor Core Technology Patents, in each case solely to develop, make, have made, use, sell, offer for sale, have sold and import Products.
License Property
Licensor is a biopharmaceutical company exploiting proprietary RNA-based drug discovery technologies to identify and commercialize novel drugs.

Antisense Compound means an oligomeric compound or analog, mimic or mimetic thereof having a sequence that is partially or wholly complementary to the sequence of a messenger RNA (pre-mRNA or mRNA), viral RNA, or noncoding RNA that directly modulates RNA expression.

Product means a pharmaceutical preparation comprising any single TS ASO or Tandem selected by Licensee. After the Project Plan has been completed, the Parties will append to this Agreement the specific sequence and chemistry of each TS ASO which constitutes the active pharmaceutical ingredient in each Product.

TS ASO means a single-stranded oligonucleotide or an analog thereof that hybridizes to TS mRNA using Watson-Crick base pairing and inhibits production of TS via an RNase-H mechanism.

1. U.S. Patent No. 6,001,1653
2. PCT Publication No. WO 93/13121
3. U.S. Patent. 5,914,396
4. U.S. Patent 61451,991
5. U.S. Patent No. 6,166,197
6. U.S. Patent No. 51919,619
7. U.S. Patent No. 5,962,425
8. U.S. Patent No. 6,143,881
9. U.S. Patent No. 5,969,116
10. U.S. Patent No. 6,346,614
11. U.S. Patent No. 6,399,754
12. U.S. Patent No. 6,326,199

Field of Use
The field of use is the identification of a lead TS ASO targeted to inhibit Thymidylate Synthase.

The drug is an antisense inhibitor of thymidylate synthase (TS), a well-known drug target that protects cancer cells from the effects of several chemotherapy treatments. In preclinical studies, antisense inhibition of TS suppressed human tumor cell growth and overcame tumor cell resistance to marketed TS-targeted drugs.

TS is an important target in a wide variety of cancers including, colorectal, breast, stomach, esophageal, head and neck cancers, and mesothelioma; it is of increasing importance in non-small cell lung cancer. In addition to interfering with the effectiveness of chemotherapy, the TS gene may also participate in causing cancer. TS is a target for several chemotherapy agents, including 5-fluorouracil (5-FU), pemetrexed (Alimta®), and raltitrexed (Tomudex®).

IPSCIO Record ID: 315857

License Grant
The parties amended the agreement in connection with the Sublicense license agreement, under which we sublicensed to a Sublicensee our rights under the license from the German Licensor. This amendment clarified payments among the parties, terminated a license we granted to Licensor in 2004, and provided for a direct license from Licensor to Sublicenssee in the event of termination of the Sublicensee agreement.
License Property
Products means RNAi products that are (i) based on the Licensor Existing IP or discovered, developed or produced using the Licensor Existing IP, (ii) based on the Licensee Existing IP and (iii) directed to the 801 gene.
6,455,674 – Hypoxia-regulated genes
6,555,667 – Hypoxia-regulated genes

RNA interference, or RNAi, is a recently discovered process that occurs naturally within cells and, facilitated by siRNA, selectively silences the activity of specific genes. Genes are the basic units of inheritance. Genes provide cells with instructions for producing proteins encoded by them. Many human diseases are caused by the abnormal behavior of proteins. The ability to stop or reduce production of a protein by selectively silencing the gene that directs its synthesis could be very beneficial in the treatment of disease.

Field of Use
The rights granted are used in the research of gene therapy for certain diseases.

Licensee is a clinical-stage pharmaceutical company engaged in discovering and developing novel RNAi interference or RNAi-based therapeutics. They have a fully integrated drug development platform that spans therapeutic target identification based on our proprietary gene discovery science and technology, to clinical drug development. Licensee has initially been focusing on RNAi-based therapeutics for the treatment of diseases associated with oxidative stress and ischemic injury.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.